Revolutionizing Clinical Trials with AI Technology
Advanced AI Platform Improves Site Selection and Study Startup
This partnership introduces innovative solutions for site identification, feasibility analysis, and automated trial optimization, enhancing cost efficiency while reducing delays for biotech and biopharma sponsors.
Transforming Clinical Research
Ryght AI, a frontrunner in the application of AI technologies within clinical trials, has joined forces with Biorasi, a renowned global clinical research organization (CRO). This partnership aims to fundamentally change how sponsors approach site selection and trial feasibility.
Both companies recognize the pressing need to tackle prevalent industry issues that result in significant financial losses for sponsors. These challenges include inaccurate site selection data, extended feasibility periods, uncertain recruitment forecasts, and unreliable site performance. The integration of Ryght AI's cutting-edge platform allows Biorasi's clients to access real-time insights, thereby converting decision-making from a hit-or-miss process into a sophisticated data-driven approach.
Dynamic AI Digital Twins for Enhanced Decision Making
According to Chris O'Brien, CEO of Biorasi, conventional feasibility models often rely on outdated self-reported data. The advent of Ryght AI's technology changes the landscape, enabling Biorasi to provide a unique solution. The combination of updated digital twins and AI-driven automation equips sponsors with recruitment forecasts based on precise, site-specific data.
Ryght AI's solution effectively addresses industry shortcomings through:
- Dynamic AI Digital Twins: Profiles of clinical research sites are frequently updated, showcasing real-time recruitment capabilities, historical performance metrics, and operational readiness.
- Automated Feasibility Workflows: Utilizing pre-set feasibility questionnaire webforms, the platform accelerates the feasibility process, reducing timelines from months to less than three weeks.
- Agentic AI Copilots: The technology supports quick protocol parsing and the automated creation of feasibility documents and outreach materials.
Tangible Benefits for Sponsors
The collaboration signals a pivotal shift in how clinical trials are conducted, reinforcing the importance of accurate and reliable study data. Simon Arkell, CEO of Ryght AI, emphasizes that their solutions not only streamline processes but also provide actionable insights for sponsors. Biorasi's clients can expect measurable advancements across various categories, including:
- Enhanced Accuracy: Improved forecasting for recruitment and budgeting minimizes financial risks.
- Reduced Delays: Accelerated site startup processes powered by intelligent automation.
- Cost Optimization: Better initial planning reduces incidents of mid-trial delays and unexpected expenses.
- Improved Efficiency: Focused engagement with research partners ensures only the most compatible sites are approached.
This partnership illustrates Ryght AI's commitment to expanding its AI-powered clinical research technology, ensuring it adheres to SOC Type 2 compliance while facilitating real-time communication between sponsors, CROs, and research sites.
About Ryght AI
Ryght AI is innovating the landscape of clinical research with an advanced platform that includes AI digital twins of clinical research sites worldwide. This revolutionary approach assists sponsors and CROs in accelerating clinical trial initiation through faster site selection and efficient feasibility processes, all enhanced by sophisticated AI capabilities. The platform also promotes effective communication between all stakeholders involved in clinical trials.
About Biorasi
Biorasi provides accelerated market entry strategies for small to midsized biotech and biopharma companies. Their extensive experience spans over two decades in clinical trials across diverse therapeutic areas like dermatology and oncology, helping clients navigate the complexities of the clinical trials landscape.
Frequently Asked Questions
What is the main goal of the partnership between Ryght AI and Biorasi?
The partnership aims to enhance clinical trial efficiency through AI-powered solutions for site selection and feasibility analysis, ultimately reducing costs and delays.
How does Ryght AI’s platform improve trial feasibility?
It provides dynamic AI digital twins of clinical sites, enabling real-time insights and data-driven decision-making, which improves accuracy in recruitment forecasts and site performance.
What are the key benefits for sponsors from this collaboration?
Sponsors can expect improved accuracy, reduced delays, cost optimization, and enhanced efficiency in trial processes.
Who benefits from the AI digital twin technology?
Both biotech and biopharma sponsors benefit from this technology as it provides tailored data that enhances the feasibility and performance of clinical trials.
How does this partnership reflect on the future of clinical trials?
It showcases a significant shift towards incorporating data-driven technologies in clinical research, making trials more efficient and effective.
